Description:
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus
epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants
with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell
death ligand 1 (PD-L1).
Title
- Brief Title: Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer
- Official Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab (MK-3475) Plus Epacadostat (INCB024360) Versus Pembrolizumab Plus Placebo as First-Line Treatment in Patients With Metastatic Non-Small Cell Lung Cancer Expressing High Levels of PD-L1
Clinical Trial IDs
- ORG STUDY ID:
654-01/ECHO-305
- NCT ID:
NCT03322540
Conditions
- Metastatic Non-small Cell Lung Cancer
Interventions
Drug | Synonyms | Arms |
---|
Pembrolizumab | MK-3475 | Treatment 1 |
Epacadostat | INCB024360 | Treatment 1 |
Placebo | | Treatment 2 |
Purpose
The purpose of this study is to evaluate the efficacy and safety of pembrolizumab plus
epacadostat compared to pembrolizumab plus placebo as first-line treatment in participants
with metastatic non-small cell lung cancer (NSCLC) expressing high levels of programmed cell
death ligand 1 (PD-L1).
Trial Arms
Name | Type | Description | Interventions |
---|
Treatment 1 | Experimental | Pembrolizumab + epacadostat | |
Treatment 2 | Active Comparator | Pembrolizumab + matching placebo | |
Eligibility Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of stage IV NSCLC without
epidermal growth factor receptor (EGFR)-sensitizing mutation, ROS1 and/or anaplastic
lymphoma kinase (ALK) translocation.
- Measurable disease based on RECIST 1.1.
- Tumor tissue that demonstrates programmed cell death ligand 1 (PD-L1) expression in ≥
50% of tumor cells (tumor proportion score [TPS] ≥ 50%) as assessed by
immunohistochemistry at a central laboratory.
- Life expectancy of at least 3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate organ function per protocol-defined criteria.
Exclusion Criteria:
- Known untreated central nervous system metastases and/or carcinomatous meningitis.
- History of (noninfectious) pneumonitis that required systemic steroids or current
pneumonitis/interstitial lung disease.
- Symptomatic ascites or pleural effusion.
- Known history of an additional malignancy, except if the participant has undergone
potentially curative therapy with no evidence of that disease recurrence for 5 years
since initiation of that therapy.
- Active autoimmune disease that has required systemic treatment in past 2 years.
- Has had an allogeneic tissue/solid organ transplant.
- Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is
not required unless mandated by the local health authority.
- Has known history of or is positive for active Hepatitis B (HBsAg reactive) or has
active Hepatitis C (HCV RNA). Note: Testing must be performed to determine
eligibility.
- History or presence of an abnormal electrocardiogram (ECG) that, in the Investigator's
opinion, is clinically meaningful.
- Use of protocol-defined prior/concomitant therapy.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Progression-free survival (PFS) of pembrolizumab + epacadostat versus pembrolizumab + placebo |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Defined as the time from randomization to the first documented progressive disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or death due to any cause, whichever occurs first. |
Secondary Outcome Measures
Measure: | Objective response rate of pembrolizumab + epacadostat versus pembrolizumab + placebo |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Defined as the proportion of participants who have a confirmed complete response (CR) or partial response (PR) perRECIST v1.1. |
Measure: | Duration of response of pembrolizumab + epacadostat versus pembrolizumab + placebo |
Time Frame: | Approximately 24 months |
Safety Issue: | |
Description: | Defined as the time from the earliest date of qualifying response until earliest date of disease progression per RECIST v1.1 or death from any cause, whichever comes first. |
Measure: | Safety and tolerability of pembrolizumab + epacadostat and pembrolizumab + placebo as measured by number of participants experiencing adverse events (AEs) |
Time Frame: | Up to 37 months |
Safety Issue: | |
Description: | AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
Measure: | Safety and tolerability of pembrolizumab + epacadostat and pembrolizumab + placebo as measured by number of participants discontinuing study drug due to AEs |
Time Frame: | Up to 37 months |
Safety Issue: | |
Description: | AE is defined as any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. |
Details
Phase: | Phase 3 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Incyte Corporation |
Trial Keywords
- non-small cell lung cancer
- programmed cell death 1 (PD-1) inhibitor
- indoleamine 2
- 3-dioxygenase 1 (IDO1) inhibitor
Last Updated
January 4, 2018